Cubist Pharmaceuticals Inc

Cubist Pharmaceuticals — Q2 2004 Earnings Presentation

12 slides from Cubist Pharmaceuticals's earnings presentation, Aug 9, 2004

  1. Slide 1: Serious Infections.

    Serious Infections.

  2. Slide 2: Summary Statement of Operations

    Summary Statement of Operations cuss) Three months ended Six months ended June30, June 30, 20042003 2004 2003 Cubicin® revenues, net $ 19257 $ - $ 19598 $ - Total revenues 1495 = 23208 _357 Cost of product revenues 4538 - 6,963 : Other operating expenses (25,371 21,558 51,958 43,974 Operating loss (

  3. Slide 3: Rising Clinical Failure Rates

    —_ CUBIST Rising Clinical Failure Rates vw or Creat Minna, tn p28 va.sn.nad torei3uumetos Dok 10 113k3Ch a6 oe oz 4 omg © S04, Aeron Sci fot Masog A Rahs Reed Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacterem

  4. Slide 4: JCM Article Summary

    JCM Article Summary cuBIST Relationship of MIC to Vancomycin Failure aia 30 MRSA Bacteremia Patients MIC<05 1.0<MIC<2.0 P valu Clinical Success Overall Success Rate 23% MIC = Minimum inhibitory Concentration a Source: JCM, June 2004, Sakoulas, et. al

  5. Slide 5: Cubist at IDSA and ICAAC 2004

    Cubist at IDSA and ICAAC 2004 cuss) Infectious Disease Society of America ~A 2004, 5 September 30 — October 3, 2004 IDSA i Boston, MA DBestont/ Interscience Conference on Antimicrobial Agents and Chemotherapy October 30-November 2, 2004 Washington, DC BS 5

  6. Slide 6: Novel Monoclonal Antibody Product

    — -B™ CUBIST Novel Monoclonal Antibody Product + Licensed from XTL Biopharmaceuticals in June 2004 + Currently in international Phase 2b trial for prevention of re-infection by hepatitis B (HBV) in liver transplant patients + Potential advantages over current standard of care — Lower infusion volume

  7. Slide 7: Summary Statement of Operations

    Summary Statement of Operations cuss) Three months ended Six months ended June30, June 30, 20042003 2004 2003 Cubicin® revenues, net $ 19257 $ - $ 19598 $ - Total revenues 1495 = 23208 _357 Cost of product revenues 4538 - 6,963 : Other operating expenses (25,371 21,558 51,958 43,974 Operating loss (

  8. Slide 8: Names of Institutions Ordering

    me ames of Institutions Ordering CUBIST As of 6/30/04 A B Cc D/OP. 8

  9. Slide 9: Orders vs. Re-orders

    # of Orders a Orders vs. Re-orders cuBIST As of 6/30/04 12,000 10,000 8,000 6.000 69% re-orders: 4.000 2,000 Lf 49% re-orders: 0 End 2003 End Q1 2004 End Q2 2004 ja Orders: 903 3,995 9,841 |@ Reorders 443 2,768 7,722 9

  10. Slide 10: Formulary Trends

    mS ae Formulary Trends cusist A &B Institutions as of 6/30/04 aes A B Overall Restricted Acceptances 151 199) 350] Unrestricted Acceptances 15 27 42! Rejections * 6 8 14 Total in Type 325 $50) 875) % Acceptance 97% 97%) 97% % Unrestricted 9% 12% 11% % Having Met 53% 43%) 46%| * All have ordered Cubi

  11. Slide 11: New vs. Existing Accounts

    (einen pay — aay — oe pe) u ci New vs. “i Accounts A as ee LP OL EOOLE OEE EEL

  12. Slide 12: Searchable text section of graphics shown above

    Searchable text section of graphics shown above [ GRA PHIC] Serious Infections. [LOGO] Serious Business. Statements made during this presentation that are not historical fact may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important f

Cubist Pharmaceuticals — Q2 2004 Earnings Presentation on 6ix